💉🩸High serum sodium predicts response to IO in mUC and mRCC
EORTC Oncology Advance

➡️Posthoc analyses of IMvigor211 (mUC, atezolizumab) and IMmotion151 (mRCC, atezolizumab+bevacizumab) trials
✅Baseline serum sodium levels of >140mmol/L : higher objective response⬆️
✅Serum

🚨 #Alerta | MPPS a través del SACS se informa que se ha recibido una ALERTA SANITARÍA emitida por el Instituto Nacional de Higiene “Rafael Rangel” sobre el producto: Tecentriq (Atezolizumab) 60 mg/ml CONCENTRADO PARA SOLICIÓN PARA INFUSIÓN P.B. 1470/23, N° lote H0346b07.

Latest network meta-analysis: Atezolizumab plus bevacizumab boosts survival in advanced HCC. A promising step forward in cancer treatment! #LiverCancer #ClinicalTrial #PatientOutcomes

'Trastuzumab etken maddeli Herceptin, Bevasizumab etken maddeli Altuzan, Niraparib etken maddeli Zejula, Nivolumab etken maddeli Opdivo, Pembrolizumab etken maddeli Keytruda, Atezolizumab etken maddeli Tecentriq gibi akıllı kanser ilaçlarının SGK tarafından karşılanmadığı

Anand V Kulkarni delivering symposium on Atezolizumab+Bevacizumab at #KPLD2024

🔥1L tiragolumab/atezolizumab + CTx in pts with ESCC #GI24
✅SKYSCRAPER-08 phase III, 461 Asian pts, 88% PDL-1 TAP ≥1%
👉 ORR: 59.7% vs 45.5%
👉 mPFS: 6.2 vs 5.4 mo
👉 mOS: 15.7 vs 11.1 mo
✅both EP met
🧐do we need both ABs? Synergy?
ESMO - Eur. Oncology

1st clinical trial ever to show that adjuvant Rx with atezolizumab+bevacizumab after ablation or surgical resection for hepatocellular carcinoma improved recurrence-free survival.

Atezo-Bev had:
👍 ⬇️ Recurrence rate...but
👎 ⬆️ Deaths & adverse events ☹️

🚨 #Alerta | el MPPS, a través del SACS, informa sobre ALERTA SANITARÍA emitida por el Instituto Nacional de Higiene “Rafael Rangel” sobre el producto: Tecentriq (Atezolizumab) 60 mg/ml CONCENTRADO PARA SOLICIÓN PARA INFUSIÓN P.B. 1470/23, N° lote H0346b07.

#GI24 ASCO Ongoing Phase III STELLAR 303 of Zanzalintinib (XL-092) plus Atezolizumab in MSS chemorefractory #crcsm
>> building up on investigator initiated effort from CAMILLA CRC cohort presented @ #GI22 ✨✨
>> looking forward to interim results in the near future.
OncoAlert

🎉Good news! IPSOS MS finally appeared today in the Lancet! Thank you to all the global investigators, patients and their families who participated in the trial. An important study showing meaningful increased survival with atezolizumab immunotherapy.
shorturl.at/PTZ34

Excited to present our poster evaluating the efficacy and safety of the addition of SBRT to atezolizumab and bevacizumab in advanced HCC at #GI24 . Thanks to Salwan Al Mutar MD MS for the 📸

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma hbsn.amegroups.org/article/view/1…

Abstract: Attention! Affimed N.V. ($AFMD 🚀Stock Price: $4.7728) reveals a major update on AFM24 + Atezolizumab for Solid tumors. Game changer?

Click for More: ainvest.onelink.me/MpR9/33tz0xdi

#BullMarket #FDA #FDA

SKYSCRAPER-08 with ~4-5 month OS benefit for tiragolumab (TIGIT inhibitor) plus atezolizumab atop chemotherapy (vs. chemo alone) as a 1st-line therapy for patients with locally advanced/metastatic esophageal squamous cell cancer #GI24

S1605 tested 12 months of atezolizumab in 74 patients with BCG unresponsive CIS±Ta/T1 and 55 patients with Ta/T1. There are many similarities with other trials in this space that were all designed based on early discussions between AUA/SUO/FDA – but also some key differences 1/n

Masterful presentation by Neeraj Agarwal, MD, FASCO on CONTACT-2; combination of atezolizumab and cabozantinib in pts with mCRPC shows improvement in PFS compared to second NHT. OS data immature. #GU24

BEATcc Trial:
🧬 Dual primary endpoints: Progression-free survival & overall survival.
⏳ Improved outcomes: Atezolizumab group showed better PFS (13.7 vs 10.4 months) & OS (32.1 vs 22.8 months).
🎗️ Atezo/Beva/chemo could redefine first-line treatment for metastatic/recurrent

El carcinoma pulmonar microcítico es una enfermedad devastadora.
Se presentan los resultados a largo plazo del ensayo IMPOWER 133.
En pacientes metastásicos la combinación de quimioterapia y atezolizumab (inmunoterapia) permite que 12 de cada 100 pacientes esté vivo a los 5 años

🔍 New IPD meta-analysis finds no association between serum magnesium levels and outcomes in metastatic urothelial carcinoma patients treated with atezolizumab. Magnesium levels don't predict outcomes or side effects. 🚫🔗
fuk Takahiro Kimura
pubmed.ncbi.nlm.nih.gov/38677745/